Objective: To investigate the predictive validity, responsiveness, and minimal clinically important difference of arm accelerometer in real-world activity of patients with chronic stroke. Design: Validation and psychometric study. Setting: Three medical centers. Subjects: Patients with chronic stroke came from three separated randomized controlled trials. Interventions: Patients with stroke received upper extremity rehabilitation programs for four weeks. Main measures: Real-world arm movements were measured by an arm accelerometer and three clinical measurement tools-the Motor Activity Log, Stroke Impact Scale, and Nottingham Extended Activities of Daily Living-administered before and after treatment. Results: A total of 82 subjects were recruited in the study (mean age: 55.32 years; mean score of FuglMeyer Assessment: 39.91). Correlations between the arm accelerometer and three clinical measurement tools were fair to moderate (Pearson's r = 0.47, 0.42, and 0.34, respectively). The correlation between the arm accelerometer and the quality of use of Motor Activity Log subscale was moderate to good (Pearson's r = 0.57). The responsiveness of the arm accelerometer from pretreatment to posttreatment was medium (standardized response mean = 0.72). The minimal clinically important difference range for the arm accelerometer was 547-751 mean counts. 
Introduction
Functional limitation of the upper extremity is one of the most common disabilities after stroke. 1 Upper extremity motor training has become an important goal of stroke rehabilitation, with the assumption that arm motor improvement in the clinic can enhance everyday function and independent living. 2 However, motor capacity measured by clinical assessment in clinic may not guarantee that this capacity can be used in daily life. The learned no-use phenomenon exhibited by some stroke patients is an example of no or seldom use of the affected arm during their daily activities, although they might preserve the capacity of performing functional tasks. 3 Therefore, using only clinical assessments to confirm the generalization of motor improvement observed in the clinic to real-world performance is difficult. An assessment that can measure real-world arm function is warranted. It can help clinicians and researchers understand the process of recovery from the functional limitations experienced by the people with stroke and the effect of arm functional limitation on realworld activities.
The arm accelerometer is an unobtrusive device designed to directly and objectively measure realworld arm physical activity. [4] [5] [6] The advantages of the arm accelerometer include the ability to record continuously for days and to measure the patient's activity in a familiar environment. During the last decade, the arm accelerometer has been used to investigate arm activity in stroke patients with different stages 4, 5 and with different levels of severity. 5, 7 It has also been used as an outcome measure to evaluate the effectiveness of interventions. 8, 9 As an objective outcome measure of real-world arm physical activity, the arm accelerometer should have sound psychometric properties. Data on the reliability and validity of the arm accelerometer have been developed. 10, 11 However, to assess the effectiveness of treatment and to measure longitudinal change over time, extensive demonstrations of clinimetric properties, including responsiveness, predictive validity, and the minimal clinically important difference, are important for clinical application.
The predictive validity of the arm accelerometer, defined as the ability of a measure to predict a future criterion outcome, was only investigated by Gebruers et al. 12 They used arm activity measured by the accelerometer to predict arm recovery, general disability, and rehabilitation status after three months of follow-up and found that activity of the affected arm had the best predictability to determine patients with acute stroke who were at risk of continued disability. On one hand, the predictability of the arm accelerometer for predicting arm functional performance and participation in activities of daily living (ADL) remained unknown. On the other hand, responsiveness of the arm accelerometer, defined as the ability of a measure to detect changes as a result of rehabilitation, 13 was only investigated in patients with acute stroke, and large responsiveness was reported. 2 Whether the results in patients with acute stroke could be applied to patients with chronic stroke remains unknown.
One study has investigated the minimal clinically important difference values of the arm accelerometer for people with acute stroke. 14 The authors used the anchor-based method, with the patients' global rating of perceived changes as the anchor, to estimate the minimal clinically important difference of the arm accelerometer. However, they did not find the minimal clinically important difference value of the arm accelerometer, possibly because no relationship was found between the mean change of duration and changes perceived by the patients. Therefore, this study used the combination of the anchor-based method with multiple anchors and the distribution-based method as an alternative method to estimate the minimal clinically important difference of the arm accelerometer.
The purposes of this study were therefore to examine the predictive validity, responsiveness, and minimal clinically important difference of real-world activity measured by the arm accelerometer in patients with chronic stroke, using three assessments of arm functional performance and ADL participation as criterion measures/anchors.
Methods
This study used pooled data for a secondary analysis. Data for 82 stroke patients were drawn from three previous and ongoing randomized controlled trials of robot-assisted arm training, mirror therapy, and combined therapy [15] [16] [17] and analyzed. The inclusion criteria for this study were (1) firstever stroke and (2) mild-to-moderate motor impairment (Fugl-Meyer Assessment of the upper extremity: 24-66). The exclusion criteria were (1) excessive spasticity at any upper extremity joints (Modified Ashworth Scale score >2), (2) cognitive impairment (Mini-Mental State Examination < 21), and (3) participation in experimental rehabilitation or drug studies within the past six months. The study was approved by the Institutional Review Board at each participating site, and all participants signed consent forms.
Participants were assigned to the robot-assisted arm training, mirror therapy, or combined therapy for 90-120 minutes of intervention every weekday for four weeks. Six trained raters, blinded to the participant's group, performed the clinical evaluations. For each participant, the same rater administered all of the measurements at pretreatment and posttreatment.
The real-world movement of the arm was measured by arm accelerometer. The arm accelerometer used in this study was the MicroMini-Motionlogger activity monitor (Ambulatory Monitoring, NY, USA; Supplementary Figure 1) . The Motionlogger activity monitor records acceleration of the arm, which is sampled at 10 Hz and summed over a 1-minute epoch. The accelerometer data were further configured using ACT-Millennium software and processed in Action4 software. Mean counts of the affected side measured by the accelerometer were used to represent affected arm activity of the participants in their natural living environment. Because wearing the arm accelerometer only on the paretic arm might remind them to use their paretic arm more frequently, an accelerometer was worn on both wrists continuously, except when bathing, for three days 18 before and immediately after the intervention. Moreover, we gave participants daily monitoring logs in which they documented their routines during the day, and we also educated patients about the proper use of the monitors. The therapists collected the daily logs after participants finished the evaluation for making sure the appropriateness of using the accelerometer by patients.
Three clinical measurement tools-Motor Activity Log, Stroke Impact Scale, and Nottingham Extended Activities of Daily Living-were used as criterion measures to estimate the predictive validity and minimal clinically important difference of the accelerometer. The Motor Activity Log, a semi-structured interview questionnaire, 19 was used to assess the patient's perception of amount of use and quality of movement of his or her affected arm during ADL outside the treatment setting. The Motor Activity Log consists of 30 common activities involving the affected arm. 19 Items are graded on a 5-point scale (0: never uses or not able to use the affected arm; 5: the ability to use the affected arm as good as before the stroke). The Motor Activity Log has shown good reliability and concurrent validity. 20 The Stroke Impact Scale is a self-reported questionnaire evaluating quality of life after stroke. It uses a 5-point Likert scale to rate 59 items assessing the effect of stroke in eight functional domains, namely, strength, memory, emotion, communication, ADL/instrumental ADL, mobility, hand function, and participation. The Stroke Impact Scale has good reliability and validity. 21 The subscales related to physical function (i.e. strength, hand function, mobility, and ADL/ instrumental ADL) were summed and used in this study. The Nottingham Extended Activities of Daily Living incorporates 22 ADL that measure the functional independence in performing the activity after stroke. It gives scores for the four subscales of mobility, domestic, leisure, and kitchen. The total score ranges from 0 to 22, with higher scores indicating better function in performing ADL. The total score of the Nottingham Extended Activities of Daily Living has good psychometric properties and is suitable to evaluate rehabilitation outcome. 22 Pearson correlation coefficients (r) were used to examine predictive validity by correlating the affected arm activity measured by the arm accelerometer before treatment with three related assessments (Motor Activity Log, Stroke Impact Scale, and Nottingham Extended Activities of Daily Living) after treatment. A Pearson's r value between 0 and 0.25 was considered low, between 0.25 and 0.5 was considered fair to moderate, between 0.5 and 0.75 was considered moderate to good, and greater than 0.75 was considered good to excellent. 23 The responsiveness of the arm accelerometer measurements was examined according to changes from pretreatment to posttreatment by the standardized response mean. The standardized response mean was estimated as the ratio of the mean change score to the SD of the mean change score. To classify the standardized response mean values, Cohen's criteria for effect size d were used as nonresponsive (<0.2), small (0.2-0.5), medium (0.5-0.8), and large (>0.8). 24 Anchor-based and distribution-based methods were adopted to triangulate the ranges of minimal clinically important difference. The anchor-based minimal clinically important difference estimate was calculated as the mean change score on the arm accelerometer, corresponding to patients who increased 10%-20% 14 on the mean score change on the three related assessments from pretreatment to posttreatment. The distribution-based minimal clinically important difference estimate was determined using Cohen's effect size benchmark, which is widely accepted. An effect size of 0.5 of the baseline score is advocated as a reasonable method to estimate the minimal clinically important difference. 25 
Results
The demographic and clinical characteristics of the participants are summarized in Table 1 .
Affected arm activity measured by the arm accelerometer before treatment was significantly correlated with the data of the three criteria outcomes (i.e. Motor Activity Log, Stroke Impact Scale, and Nottingham Extended Activities of Daily Living) after treatment ( Table 2) . Correlations between the arm accelerometer and the amount of use of the Motor Activity Log, Stroke Impact Scale, and Nottingham Extended Activities of Daily Living were fair to moderate (Pearson's r = 0.47, 0.42, and 0.34, respectively), whereas the correlation between the arm accelerometer and quality of movement of the Motor Activity Log was moderate to good (Pearson's r = 0.57).
The responsiveness of the activity in the affected arm measured by the arm accelerometer from pretreatment to posttreatment was medium (standard response mean (SRM) = 0.72; Table 3 ). As calculated from the 23 patients whose amount of use and quality of movement of the Motor Activity Log change scores reached 10%-20%, the anchorbased minimal clinically important difference estimates were 751.58 and 631.06 for the mean counts measured by the arm accelerometer, respectively (Table 3 ). The minimal clinically important difference estimate was 574.94 as calculated from the 32 patients when the Stroke Impact Scale was used as the anchor and was 614.36 for the 11 patients when the Nottingham Extended Activities of Daily Living was used as the anchor (Table 3 ). In addition, the distribution-based minimal clinically important difference estimate (i.e. 0.5 SD) for the mean counts measured by the arm accelerometer was 723.61 (Table 3) .
Discussion
In this study, the predictive validity, responsiveness, and minimal clinically important difference of real-world arm activity measured by the arm accelerometer in patients with chronic stroke have been examined. The arm accelerometer demonstrated acceptable predictive validity and responsiveness in patients with chronic stroke. The minimal clinically important difference range of the arm accelerometer was 574-751 mean counts, which improves the clinical utility of the arm accelerometer and facilitates the interpretation of the real-world change of the affected arm activity in stroke rehabilitation.
Predictive validity
The results of this study showed that the affected arm activity measured by arm accelerometer before treatment was significantly correlated with the arm function and participation in daily activities measured by the Motor Activity Log, Stroke Impact Scale, and Nottingham Extended Activities of Daily Living after treatment in patients with chronic stroke. This finding suggests that affected arm activity measured by arm accelerometer before treatment predicts arm function and participation in daily activities after four weeks of treatment. The results of this study also extend the validation study by Gebruers et al. 12 in which the predictive validity of the accelerometer was examined to predict upper limb recovery, general disability, and rehabilitation status in patients with acute stroke. This study adds knowledge to confirm that the affected arm activity measured by the arm accelerometer can also predict self-perceived functional performance and participation in ADL and indicates a positive and close relation of objective measurements with patient-oriented outcomes. Moreover, the predictive validity of the arm accelerometer was valid not only in patients with acute stroke but also in patients with chronic stroke.
Although the affected arm activity measured by the arm accelerometer has moderate to good predictability for improvement of the arm function and participation in ADL, the correlation of the arm accelerometer and the Motor Activity Log, especially quality of movement of the Motor Activity Log, was stronger than that of the arm accelerometer and the Stroke Impact Scale/Nottingham Extended Activities of Daily Living. One possible reason for this difference might be the natural characteristics of the assessments. The Stroke Impact Scale and Nottingham Extended Activities of Daily Living evaluate the patient's perceived difficulty or independence when performing ADL, which might include many contextual aspects other than just motor performance. The Motor Activity Log measures the patient's perceived use of the affected arm during ADL and emphasizes motor aspects during ADL (i.e. the amount and quality of movement performed), which may be more related to the accelerometer's data than that between the accelerometer and the Stroke Impact Scale/ Nottingham Extended Activities of Daily Living. In addition, the higher correlation found between the arm accelerometer and the quality of movement of Motor Activity Log, compared with that between the arm accelerometer and the amount of use of Motor Activity Log, may be due to the similarity of the concepts between movement quality (measured by the quality of movement of Motor Activity Log) and acceleration (obtained by the accelerometer). Kinematic studies often use acceleration-related variables (e.g. movement unit) to represent movement quality. 26 An outcome measure with good predictive validity is suggested to help practitioners make good prognostic decisions and facilitate planning for placement after discharge. 23 Therefore, the arm accelerometer could be used as an objective outcome measure before treatment to predict a patient's perceived arm use in ADL measured by Motor Activity Log after treatment, which may be helpful for planning the appropriate treatment program.
Responsiveness
A responsive instrument used as an outcome measure in an efficacy study is crucial and should be able to detect changes with improvement or deterioration. 27 The responsiveness of the arm accelerometer was medium (standardized response mean = 0.72), indicating that activity of the affected arm measured by the arm accelerometer was an acceptably responsive outcome that was sensitive to change over time. Medium responsiveness was due to the high coefficient of variance values of the arm accelerometer in our patients with chronic stoke (i.e. approximately 39% before treatment and 36% after treatment). Compared with the responsiveness value of clinical upper extremity assessments (e.g. the standardized response means of 0.95 for Action Research Arm Test, 1.27 for ABILHAND, and 1.06-1.23 for Motor Activity Log), [27] [28] [29] the magnitude of the standardized response mean for the affected arm activity measured by the arm accelerometer was slightly smaller. However, the arm accelerometer is a unique measurement that can continuously and objectively record affected arm activity in the real world, and these advantages cannot be met by functional assessments. Therefore, the arm accelerometer with medium responsiveness was still suggested to be one of the upper extremity outcome measures in stroke rehabilitation clinics and can be used in efficacy studies.
Minimal clinically important difference
Triangulation of the results based on anchor-based and distribution-based methods was used to estimate the minimal clinically important difference score of the affected arm activity measured by the arm accelerometer in the present study because no criterion standard has been established for estimating the minimal clinically important difference score. The minimal clinically important difference values derived from the three anchors of the Motor Activity Log, Stroke Impact Scale, and Nottingham Extended Activities of Daily Living ranged from 574.94 to 751.58 mean counts. These values were 15%-20% of the mean of the pretreatment mean counts (3701.88) measured by the arm accelerometer in our subject group. This finding was in agreement with the suggestion in previous studies that changes of 10%-20% of baseline could be considered as a clinically important difference for health-related measurements. 25, 30 The distributionbased minimal clinically important difference was 723.61 mean counts. When the results of the two methods were combined to establish the minimal clinically important difference, changes of 575-752 mean counts on the arm accelerometer were recommended to meet the requirement for a minimal clinically important difference. Thus, patients with chronic stroke who achieve a change score of 575 mean counts on the arm accelerometer are likely to have had a clinically important improvement in their real-world use of the affected arm. Taking our study as an example, the mean counts of the arm accelerometer in 33 patients exceeded 575, indicating that 40% of this cohort achieved clinically important improvement of real-world use of the affected arm after receiving rehabilitation. The developed minimal clinically important difference value of the affected arm activity measured by the arm accelerometer could be used as a useful index for comparing effectiveness between different treatments.
Study limitation
This study has some potential limitations. First, the minimal clinically important difference may vary, depending on the patient's baseline level of disability. A larger sample of patients with stroke with different characteristics, such as different levels of motor impairment, is needed to verify the results of the present study. Second, we pooled data from several clinical trials studying different treatment interventions. Therefore, our results cannot be attributed to the effect of a specific treatment and can be generalized only to people with chronic stroke with similar levels of motor impairments. In conclusions, the arm accelerometer demonstrated acceptable predictive validity and responsiveness in patients with chronic stroke. The affected arm activity measured by the arm accelerometer can predict arm function and participation in ADL in patients with chronic stroke, especially the motor-emphasized functional outcome (i.e. Motor Activity Log). Moreover, the affected arm activity measured by arm accelerometer was sensitive to change. Our findings suggested that the minimal clinically important difference range was 574-751 mean counts, which improves the clinical utility of the arm accelerometer and facilitates the interpretation of the real-world change of the affected arm activity in stroke rehabilitation.
Clinical Messages
• • The arm accelerometer demonstrated acceptable predictive validity and responsiveness in patients with chronic stroke. • • The change score of a patient on the arm accelerometer should reach 574-751 mean counts to be regarded as a minimal clinically important difference.
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